Recent Posts

Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah™

Novartis is pleased to announce that following a Priority Review, Health Canada has approved Kymriah™ (tisagenlecleucel/ CTL019) the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in Canada.

Archive
Search By Tags